​

Esperion Therapeutics Ownership | Who Owns Esperion Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Esperion Therapeutics Ownership Summary

Esperion Therapeutics is owned by 18.75% institutional investors, 0.38% insiders, and 80.87% retail investors. Wasatch advisors lp is the largest institutional shareholder, holding 12.56% of ESPR shares. BB Biotech AG Ord is the top mutual fund, with 5.05% of its assets in Esperion Therapeutics shares.

ESPR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEsperion Therapeutics18.75%0.38%80.87%
SectorHealthcare Stocks 57.39%9.93%32.68%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.69%10.91%62.39%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Wasatch advisors lp24.48M12.56%$53.86M
Blackrock13.98M8.26%$31.04M
Blackrock funding, inc. /de14.24M7.30%$31.32M
Vanguard group11.72M6.01%$25.77M
Bellevue group9.94M5.10%$21.88M
Two seas capital lp6.23M3.20%$13.71M
State street4.50M2.31%$9.91M
Meditor group3.79M2.24%$8.42M
Geode capital management4.34M2.23%$9.55M
Morgan stanley3.33M1.97%$7.39M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Meditor group3.79M15.57%$8.42M
Indaba capital management3.00M3.18%$6.60M
Two seas capital lp6.23M1.18%$13.71M
Diametric capital, lp354.01K0.53%$778.82K
Rhenman & partners asset management ab1.92M0.43%$4.21M
Bellevue group9.94M0.42%$21.88M
Wasatch advisors lp24.48M0.27%$53.86M
Centerbook partners lp1.31M0.17%$2.87M
Virtus etf advisers137.12K0.12%$301.66K
Platinum investment management840.05K0.11%$1.85M

Top Buyers

HolderShares% AssetsChange
Blackrock13.98M0.00%11.14M
Indaba capital management3.00M3.18%3.00M
Morgan stanley3.33M0.00%1.69M
Goldman sachs group2.75M0.00%1.45M
Wasatch advisors lp24.48M0.27%1.14M

Top Sellers

HolderShares% AssetsChange
Orbimed advisors---13.71M
Great point partners---5.79M
Bank of america corp /de/1.16M0.00%-3.38M
Marshall wace, llp---3.09M
Millennium management829.88K0.00%-2.57M

New Positions

HolderShares% AssetsChangeValue
Indaba capital management3.00M3.18%3.00M$6.60M
Hrt financial lp560.54K0.01%560.54K$1.23M
Virtu financial132.23K0.02%132.23K$291.00K
Walleye capital80.84K0.00%80.84K$177.84K
Bayesian capital management, lp65.90K0.02%65.90K$144.98K

Sold Out

HolderChange
Assetmark-8.00
Rothschild investment-100.00
Brown, lisle/cummings-190.00
Capital performance advisors llp-193.00
Southstate-314.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202486-56.78%36,541,743-71.74%180.43%38-51.28%15-65.91%
Sep 30, 20241993.11%129,297,339-5.46%661.02%78-28.44%4457.14%
Jun 30, 202419314.20%136,759,0259.15%800.65%10912.37%287.69%
Mar 31, 202416916.55%125,298,78674.83%1112.72%9751.56%26-35.00%
Dec 31, 20231458.21%71,670,941-7.32%641.28%6410.34%4025.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord9.94M5.05%-
Wasatch Ultra Growth6.68M3.39%-
Vanguard US Total Market Shares ETF6.18M3.12%-
Vanguard Total Stock Mkt Idx Inv6.18M3.12%-
iShares Russell 2000 ETF4.95M2.50%-42.84K
Wasatch Small Cap Growth Investor4.35M2.21%-43.99K
Wasatch Micro Cap4.21M2.14%-
Vanguard Institutional Extnd Mkt Idx Tr2.72M1.37%5.04K
Nuveen Quant Small Cap Equity R62.52M1.27%-
Rhenman Healthcare Equity L/S RC2 SEK1.92M0.97%-60.00K

Recent Insider Transactions

DateNameRoleActivityValue
Mar 18, 2025Halladay Benjamin Chief Financial OfficerSell$5.24K
Mar 18, 2025Warren Eric Chief Commercial OfficerSell$3.62K
Mar 18, 2025Koenig Sheldon L. President and CEOSell$19.62K
Feb 19, 2025Warren Eric Chief Commercial OfficerSell$446.45
Feb 19, 2025Halladay Benjamin Chief Financial OfficerSell$20.46

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1-7
2024 Q4-5
2024 Q3-5
2024 Q2-3

ESPR Ownership FAQ

Who Owns Esperion Therapeutics?

Esperion Therapeutics shareholders are primarily institutional investors at 18.75%, followed by 0.38% insiders and 80.87% retail investors. The average institutional ownership in Esperion Therapeutics's industry, Specialty & Generic Drug Manufacturers Stocks, is 26.69%, which Esperion Therapeutics falls below.

Who owns the most shares of Esperion Therapeutics?

Esperion Therapeutics’s largest shareholders are Wasatch advisors lp (24.48M shares, 12.56%), Blackrock (13.98M shares, 8.26%), and Blackrock funding, inc. /de (14.24M shares, 7.30%). Together, they hold 28.12% of Esperion Therapeutics’s total shares outstanding.

Does Blackrock own Esperion Therapeutics?

Yes, BlackRock owns 8.26% of Esperion Therapeutics, totaling 13.98M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 31.04M$. In the last quarter, BlackRock increased its holdings by 11.14M shares, a 392.59% change.

Who is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested?

Meditor group is Esperion Therapeutics’s biggest shareholder by percentage of total assets invested, with 15.57% of its assets in 3.79M Esperion Therapeutics shares, valued at 8.42M$.

Who is the top mutual fund holder of Esperion Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Esperion Therapeutics shares, with 5.05% of its total shares outstanding invested in 9.94M Esperion Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools